Special Issue "Theranostic Small Molecules"
Deadline for manuscript submissions: 31 August 2024 | Viewed by 113
Interests: medicinal chemistry; organic synthesis; heterocycles; Alzheimer’s disease; multi-target compounds; theranostics; steroidal compounds
2. Laboratory of Organic and Pharmaceutical Chemistry, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
Interests: medicinal chemistry; organic synthesis; heterocycles; P-glycoprotein; anticancer; antimicrobials; chiral drugs; marine natural products
Special Issues, Collections and Topics in MDPI journals
Special Issue in Pharmaceuticals: Grand Celebration: 100th Anniversary of the Discovery of Heparin
Special Issue in Pharmaceuticals: Selected papers from the 11th National Meeting of Organic Chemistry and 4th Meeting of Therapeutic Chemistry in Portugal
Special Issue in Molecules: Can Membrane Transporters Contribute to Drug Discovery?
Special Issue in Marine Drugs: Marine Products for Health and Beauty
Special Issue in Molecules: Xanthones: Themed Issue in Honor of Professor Madalena Pinto on the Occasion of Her 70th Birthday
Special Issue in Pharmaceuticals: The Story of Successful Drugs and Recent FDA-Approved Molecules
Special Issue in Molecules: Nature-Inspired Antitumor Agents
Special Issue in Molecules: Recent Contributions of Female Scientists to the Advancement of Medicinal Chemistry
Special Issue in Molecules: Molecules Medicinal Chemistry Reviews
Special Issue in Pharmaceuticals: Advances in Pharmaceutical Sciences: In Honor of Dr. Jean Jacques Vanden Eynde (JJ)
Topical Collection in Drugs and Drug Candidates: Chirality in Drugs and Drug Candidates
Special Issue in Pharmaceuticals: Selected Papers from the 8th International Electronic Conference on Medicinal Chemistry (ECMC2022)
Special Issue in Pharmaceuticals: Selected Papers from the 9th International Electronic Conference on Medicinal Chemistry (ECMC2023)
The new MDPI journal Drugs and Drug Candidates is exploring the interest of organic and medicinal chemists in a Special Issue entitled “Theranostic Small Molecules”.
The term “theranostic” was first coined in 1998 to define a material that allows the combination of diagnosis, treatment, and follow-up of a disease. The innovations in the field of theranostic small molecules are in line with ongoing efforts to develop more specific, individualized therapies (“personalized medicine”) for diverse diseases and to combine diagnostic and therapeutic capabilities into a single agent.
Since the first definition of theranostics, the concept has been progressing, becoming quite broad in its significance. An enlightening definition can be found in the dedicated journal Theranostics: “Theranostics is a concept that was originally raised to refer to the efforts of integrating imaging and therapy. As an emerging interdisciplinary field, it is related to but different from traditional imaging and therapeutics.”
The field of theranostics is quite developed especially for cancer therapy, but we can also find examples of theranostics for type 2 diabetes, and ever-expanding examples for Alzheimer’s disease, among other diseases. Within many design strategies, the theranostic molecule can explore different imaging techniques such as Positron Emission Tomography (PET), Near-Infrared Fluorescence (NIRF) or Magnetic Resonance Imaging (MRI), depending on the target disease.
Original research papers, review papers or accounts are welcome for submission to this Special Issue. Submissions will be rigorously peer-reviewed.
Dr. Hélio Albuquerque
Dr. Maria Emília De Sousa
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Drugs and Drug Candidates is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- (non)targeted theranostics
- leveraged theranostics
- NIRF theranostics
- isotope-labelled theranostics
- SNC diseases
- endocrin disorders